Shilpa Medicare’s marketing partner, Amneal Pharmaceuticals, has launched PEMRYDI RTU (Pemetrexed injection 10 mg/mL), the first ready-to-use pemetrexed formulation in the US market.

The product has already been granted permanent J-code (J9324) by U.S. Centers for Medicare & Medicaid Services (CMS).